Global Biotech Weekly

This week, we are revisiting the small to mid-cap PDUFA left for the quarter. At this stage in development, these trials aim to test the safety, side effects, and best dose of a new treatment. UroGen Pharma (NASDAQ: URGN) has a market cap of US$181m and a float of approximately 43.76m shares. The co A regulatory decision is expected on 13 June 2025, for UGN-102 (VesiGel), a mitomycin-based intravesical th Nuvation Bio (NYSE: NUVB) is a clinical-stage oncology company with a market cap of approximately US$784m a A PDUFA date of 23 June 2025, has been set for Taletrectinib, a selective ROS1/NTRK inhibitor under priorit Unicycive Therapeutics (NASDAQ: UNCY) is a micro-cap company with a valuation near US$65m. It has limited r The FDA has assigned a PDUFA date of 28 June 2025, for Oxylanthanum Carbonate (OLC), a novel lanthanum-base